Tested Applications
| Positive IHC detected in | human breast cancer tissue, human colon cancer tissue, human liver cancer tissue, human ovary tumor tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
28016-1-AP targets BPTF in IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag27761 Product name: Recombinant human BPTF protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 459-657 aa of NM_004459 Sequence: MEPIGYDRSRRKYWFLNRRLIIEEDTENENEKKIWYYSTKVQLAELIDCLDKDYWEAELCKILEEMREEIHRHMDITEDLTNKARGSNKSFLAAANEEILESIRAKKGDIDNVKSPEETEKDKNETENDSKDAEKNREEFEDQSLEKDSDDKTPDDDPEQGKSEEPTEVGDKGNSVSANLGDNTTNATSEETSPSEGRSP Predict reactive species |
| Full Name | bromodomain PHD finger transcription factor |
| Calculated Molecular Weight | 338 kDa |
| GenBank Accession Number | NM_004459 |
| Gene Symbol | BPTF |
| Gene ID (NCBI) | 2186 |
| RRID | AB_2918139 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q12830 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Bromodomain PHD finger transcription factor (BPTF), a histone-binding component of NURF (nucleosome-remodeling factor), plays an important role in catalyzing ATP-dependent nucleosome sliding and facilitating transcription of chromatin. It has been reported that BPTF maybe a novel and potential therapeutic target in hepatocellular carcinoma. BPTF may also regulate transcription through direct binding to DNA or transcription factors.(PMID: 30419422)
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for BPTF antibody 28016-1-AP | Download protocol |
| IHC protocol for BPTF antibody 28016-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The BPTF Polyclonal antibody (Cat# 28016-1-AP) has 1 citation to date. It was cited in Biomolecules (2024), in a study investigating lumbrokinase's synergistic effects with bevacizumab and chemotherapeutics in non-small cell lung cancer treatment via BPTF/VEGF and NF-κB/COX-2 signaling pathway inactivation. The associated research fields include oncology, specifically lung cancer therapeutics, and chromatin remodeling/signaling pathway biology.
| Species | Application | Title |
|---|---|---|
Biomolecules Lumbrokinase Extracted from Earthworms Synergizes with Bevacizumab and Chemotherapeutics in Treating Non-Small Cell Lung Cancer by Targeted Inactivation of BPTF/VEGF and NF-κB/COX-2 Signaling |
